Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer

Technology appraisal guidance
Reference number: TA503
Published: 31 January 2018

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 231 KB)

Published:

31 January 2018

Final appraisal determination: 1

Final appraisal determination: 1
Committee papers (PDF 3.66 MB)

Published:

14 December 2017
Final appraisal determination document (PDF 316 KB)

Published:

14 December 2017
Public committee slides (PDF 257 KB)

Published:

14 December 2017

Draft guidance: 1

Draft guidance: 1
Public committee slides clinical presentation slides (PowerPoint 986 KB)

Published:

01 September 2017
Public committee slides cost presentation slides (PowerPoint 132 KB)

Published:

01 September 2017
Committee papers (PDF 21.09 MB)

Published:

01 September 2017
Appraisal consultation document (PDF 327 KB)

Published:

11 September 2017

Invitation to participate

Final scope (PDF 239 KB)

Published:

15 March 2017
Final matrix (PDF 340 KB)

Published:

15 March 2017
NICE's response to comments on the draft scope and provisional matrix (PDF 289 KB)

Published:

15 March 2017
Equality impact assessment (Scoping) (PDF 174 KB)

Published:

15 March 2017